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Statins
Still in Pursuit of Pleotrophic Effects*
Matthew J. Budoff, MD
Torrance, California
Statins have long been known to have multiple pleotrophic
effects, those beyond lowering cholesterol alone. These
additional benefits of statins (i.e., inflammation reduction,
plaque stabilization, endothelial function improvement)
have most likely been partially responsible for the cardio-
vascular benefits of this class of agents. Inflammation
substudies from 2 secondary prevention trials—PROVE-IT
(Pravastatin or Atorvastatin Evaluation and Infection-TIMI
22) (1) and REVERSAL (Reversing Atherosclerosis With
Aggressive Lipid Lowering) (2)—have shown that intensive
therapy with atorvastatin 80 mg compared with pravastatin 40
mg achieves a greater decrease in low-density lipoprotein
(LDL) cholesterol and C-reactive protein (CRP) levels, and
together, they are associated with a greater reduction in
clinical events and progression of atherosclerotic plaque burden.
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However, just evaluating CRP has proved to be a poor
predictor of cardiovascular events and is unlikely the pri-
mary mechanism of benefit (3). New research suggests that
statins modify the epicardial adipose tissue (EAT), which is
the visceral fat around the heart, and this effect may be
independent of a lipid-lowering effect. Alexopoulos et al. (4)
in this issue of the Journal, show the differential effect of
high- and moderate-dose statins (using the same statin
doses as those used in both PROVE-IT and REVERSAL)
on the epicardial fat surrounding the heart. This study
demonstrated that statin therapy induced EAT regression,
and intensive therapy (atorvastatin 80 mg/day) was more
effective than moderate-intensity therapy (pravastatin 40
mg/day). The investigators conclude that this effect does not
seem to be linked to LDL lowering. This raises the
interesting questions of whether this represents another
pleotrophic effect of the statins and whether this is a direct
anti-inflammatory effect, manifesting by decreasing the
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There have been several notable failures in the attempt
to discern the relative benefit of the nonlipid-lowering
pleotrophic effects of statins. Notably, the aforementioned
PROVE-IT trial (1) demonstrated that the lower LDL
attained with atorvastatin was associated with fewer cardio-
vascular events (CVEs), despite a hypothesis that pravasta-
tin, a statin previously shown to have significant pleotrophic
properties, would be at least as good in decreasing CVEs.
Following this, the JUPITER (Justification for the Use of
Statins in Prevention: An Intervention Trial Evaluating
Rosuvastatin) trial (5) demonstrated reverse epidemiology
for an anti-inflammatory effect benefit. In those persons
with high-sensitivity CRP (hsCRP) levels above a median
of 4.3 mg/dl randomized to rosuvastatin, there was signif-
icantly less benefit than in those who started with an hsCRP
level below the median (p  0.015). Kaul et al. (5)
demonstrated that “the benefit is significantly greater in
those with an hsCRP level lower than the median (4.2 mg/l)
and nonsignificantly greater in those with an hsCRP level
lower than 3 mg/l. These data imply an inverse dose-response
of hsCRP in the treatment arm.” This undermines the concept
of statins’ effect on CVEs being related to inflammation
reduction directly and higher levels of inflammation pre-
dicting better CVE reduction. JUPITER demonstrated that
those patients with lower hsCRP had a greater benefit from
rosuvastatin, and, unfortunately, those with hsCRP 2 mg/dl
were excluded. Furthermore, JUPITER failed to demon-
strate any benefit in the subset of patients with an isolated
CRP increase. Thus, if we hope to have a better under-
standing of the true benefits of therapies, we need better
biomarkers to evaluate their individual effects.
Although numerous studies have documented the prog-
nostic value of coronary artery calcium on noncontrast
computed tomography of the heart, more recent studies are
reporting the independent and incremental prognostic im-
portance of the fat surrounding the heart (6). This EAT (or
pericardial fat) is associated with multiple markers of in-
flammation, vascular dysfunction, and oxidative stress and
also predicts major CVEs (6–8). Investigators have sug-
gested that excessive nonsubcutaneous fat deposition may
play a role in the function of surrounding tissues and organs
through the inflammatory cytokines and free fatty acid
secretion, leading to ischemia, cardiovascular disease, and
coronary obstruction (7–9).
Epicardial fat volume, as a direct measure on computed
tomography, may afford us newer insights into the differ-
ential effects of commonly used therapies. The potential use
in evaluating drug therapy on cardiovascular disease risk and
metabolism is significant. Newer oral hypoglycemic, anti-
inflammatory, and lipid-lowering therapies can all poten-
tially benefit from better techniques to evaluate their non-
cholesterol benefits. This study further validates the need to
add to serum biomarkers with better techniques that can
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ever, before we use this new technique in clinical practice,
outcome studies validating that progression of EAT is
associated with increased CVEs and/or regression is asso-
ciated with cardiovascular protection need to be conducted.
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